PF-00299804
Jump to navigation
Jump to search
| PF-00299804 | |
|---|---|
| Term | PF-00299804 |
| Short definition | PF-00299804 - A drug used to treat non-small cell lung cancer that has spread, has not yet been treated and has certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
PF-00299804 - A drug used to treat non-small cell lung cancer that has spread, has not yet been treated and has certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. PF-00299804 blocks certain proteins that can prevent cancer cells from growing and kill them. It's a type of tyrosine kinase inhibitor. Also called dacomitinib and vizimpro
External links
- Medical encyclopedia article on PF-00299804
- Wikipedia's article - PF-00299804
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski